Linden Thomas Advisory Services’s Jazz Pharmaceuticals JAZZ Stock Holding History

Linden Thomas Advisory Services’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.32M	Sell	5,489 -29	-0.5%	-$6.35K	0.11%	306
2026 Q1	$1.04M	Buy	+5,518	New	+$964K	0.1%	311

Other funds holding JAZZ

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

ACM

Argent Capital Management St Louis, Missouri $3.17B AUM 36.16% 1-Year Est. Return

WCM

Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

BCM

BTC Capital Management Des Moines, Iowa $1.65B AUM 27.85% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Linden Thomas Advisory Services's JAZZ Position: Q2 2026 in Review

Linden Thomas Advisory Services reduced its Jazz Pharmaceuticals (JAZZ) stake by 0.53% in Q2 2026, selling an estimated $6.35K and leaving 5,489 shares worth $1.32M. The position accounts for 0.11% of the portfolio, ranked #306.

Linden Thomas Advisory Services first reported a position in JAZZ in Q1 2026 and has held it in 2 quarters since. 130 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

Linden Thomas Advisory Services held 5,489 shares of Jazz Pharmaceuticals worth $1.32M as of Q2 2026.
Linden Thomas Advisory Services sold 29 Jazz Pharmaceuticals shares in Q2 2026, an estimated $6.35K.
Jazz Pharmaceuticals made up 0.11% of Linden Thomas Advisory Services's portfolio in Q2 2026, its #306 holding.
Linden Thomas Advisory Services first reported a position in Jazz Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
130 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Linden Thomas Advisory Services's 13F filing for Q2 2026, filed 16 Jul 2026.